Enterprise Value
208.2M
Cash
384.9M
Avg Qtr Burn
-56.75M
Short % of Float
34.70%
Insider Ownership
17.54%
Institutional Own.
64.47%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Cemacabtagene Ansegedleucel (cema-cel) Details Cancer, Diffuse large B cell lymphoma | Phase 2 Data readout | |
Cemacabtagene ansegedleucel, or cema-cel [ALLO-501A (CD19)] Details Cancer, Non-Hodgkin lymphoma, Diffuse large B cell lymphoma | Phase 2 Data readout | |
ALLO-647 (Anti-CD52 mAb) Details Cancer, Diffuse large B cell lymphoma | Phase 2 Update | |
ALLO-316 (CD70) Details Renal cell carcinoma, Cancer, Solid tumor/s | Phase 1 Data readout | |
ALLO-715 (BCMA) Details Cancer, Multiple myeloma | Phase 1 Update | |
ALLO-605 (BCMA) Details Multiple myeloma, Cancer | Phase 1 Update |